$57.33
0.59% day before yesterday
Nasdaq, Dec 27, 10:00 pm CET
ISIN
US92346J1088
Symbol
VCEL

Vericel Corporation Stock price

$57.33
-0.43 0.74% 1M
+10.42 22.21% 6M
+21.72 60.99% YTD
+21.95 62.04% 1Y
+15.36 36.60% 3Y
+39.88 228.54% 5Y
+54.34 1,817.39% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
-0.34 0.59%
ISIN
US92346J1088
Symbol
VCEL
Sector

Key metrics

Market capitalization $2.83b
Enterprise Value $2.81b
P/E (TTM) P/E ratio 917.28
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 12.38
P/S ratio (TTM) P/S ratio 12.47
P/B ratio (TTM) P/B ratio 10.97
Revenue growth (TTM) Revenue growth 22.48%
Revenue (TTM) Revenue $226.84m
EBIT (operating result TTM) EBIT $-1.23m
Free Cash Flow (TTM) Free Cash Flow $-12.02m
Cash position $118.40m
EPS (TTM) EPS $0.06
P/E forward 465.39
P/S forward 11.80
EV/Sales forward 11.71
Short interest 12.90%
Show more

Is Vericel Corporation a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Vericel Corporation Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Vericel Corporation forecast:

8x Buy
100%

Analyst Opinions

8 Analysts have issued a Vericel Corporation forecast:

Buy
100%

Financial data from Vericel Corporation

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
227 227
22% 22%
100%
- Direct Costs 65 65
8% 8%
29%
162 162
29% 29%
71%
- Selling and Administrative Expenses 133 133
22% 22%
59%
- Research and Development Expense 25 25
16% 16%
11%
3.95 3.95
179% 179%
2%
- Depreciation and Amortization 5.18 5.18
36% 36%
2%
EBIT (Operating Income) EBIT -1.23 -1.23
91% 91%
-1%
Net Profit 3.55 3.55
135% 135%
2%

In millions USD.

Don't miss a Thing! We will send you all news about Vericel Corporation directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Vericel Corporation Stock News

Positive
Seeking Alpha
9 days ago
Vericel Corporation, specializing in cellular therapies for sports medicine and severe burn care, has seen a 40% rise in its stock recently. Core products include MACI, NexoBrid, and Epicel, with Q3 revenues rising 27% year-over-year to $57.9 million, beating expectations. The company is turning the corner on profitability, but valuations look stretched at current trading levels.
Positive
Investors Business Daily
25 days ago
None of our picks is Nvidia or Amazon or Tesla. Investors may wish to widen the aperture to find the best stocks for outsize earnings growth.
Neutral
Investors Business Daily
about one month ago
The top five biotech stocks today have several commonalities. Among them are strong ratings.
More Vericel Corporation News

Company Profile

Vericel Corp. engages in the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of patients with diseases. Its product portfolio includes MACI and Epicel. The MACI portfolio is FDA-approved product that applies the process of tissue engineering to grow cells on scaffolds using healthy cartilage tissue from the patient's own knee. The Epicel portfolio provide skin replacement for patients who have deep dermal or full thickness burns. The company was founded on March 24, 1989 and is headquartered in Cambridge, MA.

Head office United States
CEO Dominick Colangelo
Employees 314
Founded 1989
Website www.vcel.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today